Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in castration-resistant prostate cancer
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Prostate International
- Vol. 9 (1) , 31-41
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Education, Science and Technology (2018R1A2B6001693)
This publication has 19 references indexed in Scilit:
- Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing miceCancer Letters, 2013
- Is TRAIL the holy grail of cancer therapy?Apoptosis, 2009
- Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2008
- Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene TherapyCancer Research, 2007
- Stem Cell Transplantation: The Lung BarrierTransplantation Proceedings, 2007
- Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapyCancer Science, 2005
- Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer AgentsJNCI: Journal of the National Cancer Institute, 2004
- Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAILCancer Gene Therapy, 2002
- Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of NeurotoxicityBiochemical and Biophysical Research Communications, 1999
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996